Pediatric cancer treatment based on Nanosmart platform obtains FDA’s orphan drug status
The new drug product is a formulation of dactinomycin indicated to treat Ewing’s sarcoma, a rare type of childhood bone cancer. Orphan drug designation was awarded to the
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.